CD4 and neoplasm: In this network meta-analysis, the clinical effective rate, KPS score, T cell subsets (CD3+, CD4+, CD4+/CD8+), serum tumor markers (CA125, HE4), and adverse events were all shown to be 5 interesting outcomes.